NEW YORK (GenomeWeb News) – Swiss proteomics firm Biognosys said this week that it has secured $1.0 million in funding in the form of a convertible loan.

The company, which specializes in targeted proteomics and mass spec-based biomarker discovery, said it will use the money to expand its commercial operations and product development.

Biognosys was spun out of Ruedi Aebersold's laboratory in 2008 at the Swiss Federal Institute of Technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.